Prosensa Holding N.V. To Webcast Conference Call Discussing 1st Quarter 2014 Financial Results And Corporate Update On May 20, 2014

Leiden, The Netherlands, May 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that theCompany will host a conference call and live audio webcast onTuesday, May 20, 2014 at 8:00 a.m. US Eastern Time (2:00 p.m.Central European Time) to report its first quarter financialresults and provide a corporate update.

In order to participate in the conference call, please dial1-877-407-9170 (US Domestic toll-free). International dial-innumbers and an audio webcast can be accessed under "Events &Presentations" through the Investors & Media section of theProsensa corporate website at

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engagedin the discovery and development of RNA-modulating therapeutics forthe treatment of genetic disorders. Its primary focus is on rareneuromuscular and neurodegenerative disorders with a large unmetmedical need, including Duchenne Muscular Dystrophy (DMD), MyotonicDystrophy and Huntington's Disease.

Prosensa's current portfolio includes six compounds for thetreatment of DMD, all of which have received orphan drug status inthe United States and the European Union. The compounds use aninnovative technique called exon-skipping to provide a personalizedmedicine approach to treat different populations of DMD patients.
CONTACT: Prosensa Holding N.V.         Celia Economides, Senior Director IR & Corporate Communications         Phone: +1 917 941 9059         Email:

Prosensa Holding B.V. Logo